In vitro CTL assay.
Splenocytes and LN cells from C57BL/6 mice were isolated 10 and 30 days after IM injection with AAV-CMV-ova and re-stimulated in vitro for 6 days using irradiated (6000 rad) ova-expressing E.G7-OVA cells as feeder cells 22 . Culture media were RPMI1640 containing 10% FBS, 1mM sodium pyruvate, MEM non-essential amino acids, 50 µM M2-mercaptoethanol, 10 mM HEPES, and 5 units/ml rhIL-2. Subsequently, 
Results

AAV-mediated ova expression derived from murine skeletal muscle is transient.
AAV-CMV-ova vector was injected into quadriceps and tibialis anterior muscles of the left hind limb of BALB/c mice at doses of 1x10 11 vector genomes [vg] or 1x10 12 vg/animal. Systemic ova expression was monitored by ELISA assay on plasma samples.
Data from Fig. 1A demonstrate that ova expression was vector dose-dependent and transient: Circulating levels up to 30 ng/ml were detectable only at 2 weeks post gene delivery, but declined to undetectable levels by week 4. Virtually identical appearance and loss of transgene expression was obtained in BALB/c mice transgenic for DO11.10 TCR (Fig. 1C) . Since systemic transgene expression was undetectable by week 4 without evidence for antibody to ova at this time (Fig. 1B ,D, and data not shown), we suspected a cellular immune response. At a dose of 1x10 12 vg/mouse, IgG1 antibody to ova was measured at low titer by 5-6 weeks in both strains (Fig. 1B,D) . 
Destruction of muscle fibers eliminates expression.
To test the hypothesis that CTL responses to ova have been generated, we sacrificed DO11.10 transgenic mice at days 10 and 30 after IM injection of 1x10 12 vg/animal (n=5 per time point) and analyzed cross-sections of muscle tissue by immunohistochemistry.
As shown in Fig. 2A and B, there was a strong inflammatory reaction in AAV-CMV-ova injected muscle at day 10. Substantial inflammatory infiltrate was seen after H&E stain.
Tissue damage was evident, whereas tissue sections from the un-injected leg showed normal morphology (Fig. 2C ). Immunoflourescence staining for ova expressing muscle fibers was positive at day 10, but not at day 30 ( Fig. 2A ,B,J). While there were a few areas showing ova-expressing fibers at day 10 without cellular infiltrate (Fig. 2G ), most ova-expressing fibers (>70%) were surrounded by CD8 + cells. A representative micrograph is shown in Fig. 2H . At day 30, strong inflammatory infiltration was still observed in tissue sections of transduced muscle. Some level of CD8 + cellular infiltrate remained, while no ova expression was detectable at this time point (Fig. 2J ). An example of dead muscle fibers surrounded by inflammatory cells is depicted in Fig. 2D .
Active muscle fiber regeneration (characterized by emergence of fibers with central nuclei) was seen at both time points, which was extensive at day 30 (Fig. 2E ). These observations provide strong evidence that ova expression evoked a CTL response, which caused muscle fiber destruction and disappearance of ova expression. IM administration of AAV-CMV-GFP (1x10 12 vg/animal) resulted in sustained GFP expression without inflammation in DO11.10 TCR transgenic BALB/c mice (Fig. 2Q, R) . This indicates that immune responses upon AAV-CMV-ova injection were antigen-specific and were directed to the transgene product rather than viral antigens. Use of a muscle-specific promoter for transgene expression did not prevent the inflammatory response in transduced muscle, which again was associated with a CD8 + cell infiltrate at the site of transgene expression (Fig. 2T,U) . The synthetic C5-12 promoter used in these experiments is entirely comprised of muscle-specific enhancer/promoter elements and had been shown by others to be myocyte-specific in a transgenic animal model 32 .
CD4 + T cell activation in draining lymph nodes.
To further study T cell activation, we analyzed ova-specific T cell responses by various For
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Taken together and consistent with inflammatory reactions, these data demonstrate a predominantly Th1-driven local immune response, with some level of Th2 immunity. In order to further correlate in vitro data on Th1 responses with in vivo data on an inflammatory reaction in injected muscles, we performed additional immunostaining and found infiltrate of CD4 + TCR + cells as well as of cells producing IFN-γ cytokine (Fig. 2L- O) 33 .
We also measured in vitro lymphocyte proliferation for draining LN cells and splenocytes
of AAV-CMV-ova injected DO11.10 mice. At day 10 after gene transfer, splenocytes failed to proliferate to ova, cells from non-draining LN showed substantially reduced proliferation, and cells from draining LN had mildly reduced proliferative responses (Fig.   3H,I ). At day 30 after vector administration, ova-specific proliferation was similar for non-draining LN cells and splenocytes compared to controls, while ova-specific proliferation was increased for draining LN cells (Fig. 4H,I ).
Induction of CD8
+ CTLs to ova.
Data presented above pointed toward destruction of AAV-CMV-ova transduced muscle fibers by a cytotoxic CD8 + T lymphocyte response to ova. This was studied in more detail by IM administration of AAV-CMV-ova vector (1x10 12 vg/animal) in wild-type or CD8-deficient C57BL/6 mice. Similar to studies in BALB/c mice, systemic ova expression was transient in wild-type mice, although somewhat more prolonged in C57BL/6 compared to BALB/c mice (Fig. 6A) . Only one of 4 wild-type mice injected IM with vector formed antibody to ova during the course of the experiment (data not shown), while all animals lost systemic expression by 6 weeks (Fig. 6A) . Again, sections of muscle tissue showed an inflammatory reaction, CD8 + cell infiltrate, and muscle regeneration (Fig. 6B, left column) . In vitro CTL assay using MHC class I compatible target cells demonstrated a cytolytic response to ova expressing cells (Fig. 6C-E) . CTL responses were also induced when AAV-C5/12 vector containing a muscle-specific promoter was injected, albeit with a 4-to 8-fold lower in vitro cytolytic activity compared to the CMV-driven construct (Fig. 6F,G) . In contrast to wild-type mice, CD8-deficient C57BL/6 mice showed sustained systemic ova expression and lack of inflammation after IM administration of AAV-CMV-ova, supporting the interpretation that CD8 + T cell activation was required for muscle fiber destruction ( Fig. 6A and Fig.   6B , right columns). In contrast to T helper cell responses, CTLs were detected in spleens in addition to draining LN. No T cell proliferation was observed in draining LNs when vector was injected that contained the ova cDNA in antisense orientation (data not shown). By day 10, an inflammatory reaction was evident in AAV-CMV-ova transduced, but not in AAV-null vector transduced muscle, with higher vector doses yielding more severe inflammation (Fig. 7D ). Inflammatory infiltrate included CD8 + and IFN-γ + cells (Fig. 7E,F) . 
Discussion
In animal models, AAV2-mediated F.IX gene transfer to the liver often resulted in sustained expression even if the transgene product represented a neo-antigen such as human F.IX in mice or non-human primates, canine F.IX in hemophilia B dogs with a F.IX nonsense mutation, or murine F.IX in hemophilia B mice with a large F.IX gene deletion 7, 12, 15, 16, 36 . Sustained hepatocyte-derived transgene expression has been shown to be associated with F.IX-specific tolerance induction 15 . In contrast, IM administration of AAV2 vector expressing these transgene products in the identical strains of animals invariably caused a neutralizing antibody response to F.IX, which has been shown to require T help 5, 36, 11 . Similar immune responses have been described to several other secreted transgene products in AAV gene transfer to skeletal muscle. We sought to develop a model system that will allow identification of immunological mechanisms underlying these observations.
Following ova gene transfer to mice transgenic for ova-specific DO11.10 TCR, we can physically identify CD4 + T cells with TCR specific to transgene product-derived peptide-MHC II complex 37 One can now pinpoint where T cell activation takes place and where these cells traffic subsequently.
In vitro CTL assays and experiments in CD8-deficient mice support the conclusion that by cross-priming is 50,000-fold more efficient for cell-associated ova than for soluble ova 40 . We therefore assume that ova protein associated with muscle cell surfaces rather than circulating ova was responsible for CTL activation in our study. It remains unclear at this point, whether and how interactions between cell membrane surfaces of transduced muscle fibers and dendritic cells result in antigen up-take and processing. Others have shown that very high levels of systemic F.IX transgene expression achieved by administration of high dose AAV-1 vector may not cause or at least down-regulate an immune response 43, 44 . Interestingly, our study shows transient decreases in T cell proliferation and cytokine release (IL-2, IL-10, and IFN-γ), and a transient increase in IL-4 production in spleens and non-draining LN of DO11.10 transgenic mice after muscledirected ova gene transfer. We propose that systemic protein delivery, similar to intravenous injection of antigen, may lead to tolerogenic antigen presentation at sites outside the transduced muscle. Additional experiments will be necessary to test this hypothesis.
There are substantial differences in T cell activation between hepatic and muscle-directed routes of AAV vector administration, which appears to be largely independent of the promoter used for transgene expression, but may be influenced by levels of the transgene product 7, 9, 12, 15, 26, 44 . These observations are consistent with the notion that during T cell activation, the immune system relies on signals that are provided by tissues 45 . Therefore, the target tissue plays a crucial role in T cell activation during AAV-mediated transfer of a gene encoding a secreted protein that represents a neo-antigen. In contrast to the capacity of the liver to promote tolerance induction and sustained systemic transgene expression, a local immune response is initiated in transduced skeletal muscle.
Generation of antigen-specific CD4 + T helper cell responses combined with CD8 + T cell or B cell activation ultimately eliminates transgene expression, which represents a severe limitation to use of skeletal muscle for systemic therapeutic protein delivery.
